Atlas Trials

Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]

Clinical trial NCT03747120 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03747120
Sponsor
University of Texas Southwestern Medical Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-positive Breast CancerBreast Cancer
Start date
2019-01-25
Primary completion
2024-11-08
Enrollment
138

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.